HeartSciences (HSCS) EBITDA Margin (2021 - 2025)

HeartSciences (HSCS) has reported EBITDA Margin for 5 consecutive years, with 85713.23% the latest figure, recorded in Q4 2025.

• Quarterly EBITDA Margin changed N/A year-over-year to 85713.23% in Q4 2025, while the trailing twelve-month figure through Apr 2026 was 96946.89% (down 5310137.0% YoY) and the FY2026 annual result came in at 194787.38%, down 277425.0% from the prior year.
• EBITDA Margin advanced to 85713.23% in Q4 2025 per HSCS's latest filing, from 98637.84% in the prior quarter.
• Over the last five years, EBITDA Margin for HSCS reached as high as 9011.84% in Q3 2021 and fell as low as 98637.84% in Q3 2025.
• A 5-year average of 48780.2% and a median of 44418.82% in 2025 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2022 — EBITDA Margin slumped 3567869 bps — and 2024, when it soared 5676700 bps.
• Year by year, EBITDA Margin stood at 9011.84% in 2021, then slumped by 396 bps to 44690.53% in 2022, then advanced by 10 bps to 40254.95% in 2023, then soared by 74 bps to 10376.75% in 2024, then tumbled by 726 bps to 85713.23% in 2025.
• According to Business Quant data, EBITDA Margin over the past three periods registered 85713.23%, 98637.84%, and 44147.1% for Q4 2025, Q3 2025, and Q2 2025 respectively.